1Michel M.C.,Vrydag W.Alphal-lpha2-and beta-drenoceptom in the urinary bladder,urethraand proatate[J].Br J Pharmacol,2006,147(s2):88-119.
2Dmochowski RR, Staskin D. Overactive bladder in men: special considerations for evaluation and management. Urology, 2002, 60 (5 Suppl 1) : 56-62.
3Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastroin- testinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol,2005, 174(4) :1334-1338.
4Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tam- sulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled triM. JAMA, 2006, 296(19) : 2319-2328.
5Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological character- ization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull, 2007, 30(1) : 54-58.
6Dobrek L, Juszczak K, Wyczolkowski M, et al. Current manage- ment and future perspectives of overactive bladder(OAB) pharma- cotherapy [ J ]. Acta Pol Pharm ,2011,68 (6) :807-821.
7Dmochowski RR, Staskin D. Overactive bladder in men: special considerations for evaluation and management[ J]. Urology,2002, 60(5 Suppl 1) : 56-62.
8Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gas- troin-testinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective,random- ized, controlled muhicenter study [ J ]. J Urol, 2005,174 (4) : 1334-1338.
9Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tam- sulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial [ J ]. JAMA, 2006,296(19) : 2319-2328.
10Nickell K, Boone TB. Peripheral neuropathy and peripheralnerve injury[ J]. Urol clin North AM. 1996,23 (3) :491-500.
